Evaluating many treatments and biomarkers in oncology: A new design

Journal of Clinical Oncology

Volumn 31, Issue 36, 2013, Pages 4562-4568

  Kaplan, Richard ^a   Maughan, Timothy ^b   Crook, Angela ^a   Fisher, David ^a   Wilson, Richard ^c   Brown, Louise ^a   Parmar, Mahesh ^a  

^a MEDICAL RESEARCH COUNCIL   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; B RAF KINASE; BIOLOGICAL MARKER; K RAS PROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PLACEBO; PROTEIN KINASE B; TUMOR MARKER;

ARTICLE; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL PROTOCOL; COLORECTAL CANCER; GENE MUTATION; HUMAN; ONCOGENE N RAS; ONCOLOGY; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SIGNAL TRANSDUCTION; STUDY DESIGN; TREATMENT RESPONSE; CLINICAL TRIAL (TOPIC); COLORECTAL TUMOR; EVIDENCE BASED MEDICINE; METABOLISM; METHODOLOGY; MOLECULARLY TARGETED THERAPY; NEOPLASM; PATHOLOGY; PREDICTIVE VALUE; PROGNOSIS; SAMPLE SIZE; STANDARD; TREATMENT OUTCOME; COLORECTAL NEOPLASMS; NEOPLASMS; PROCEDURES; STANDARDS; TRENDS;

ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; COLORECTAL NEOPLASMS; EVIDENCE-BASED MEDICINE; HUMANS; MOLECULAR TARGETED THERAPY; NEOPLASMS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RESEARCH DESIGN; SAMPLE SIZE; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 84894477310     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2013.50.7905     Document Type: Article

References (43)

1. Sargent DJ, Conley BA, Allegra C, et al: Clinical trial designs for predictive marker validation in cancer treatment trials. J Clin Oncol 23:2020-2027, 2005 (Pubitemid 46211382)
2. Mandrekar SJ, Sargent DJ: Clinical trial designs for predictive biomarker validation: Theoretical considerations and practical challenges. J Clin Oncol 27:4027-4034, 2009
3. Freidlin B, McShane LM, Korn EL: Randomized clinical trials with biomarkers: Design issues. J Natl Cancer Inst 102:152-160, 2010
4. Lee JJ, Xuemin G, Suyu L: Bayesian adaptive randomization designs for targeted agent development. Clin Trials 7:584-596, 2010
5. Mandrekar SJ, Sargent DJ: Predictive biomarker validation in practice: Lessons from real trials. Clin Trials 7:567-573, 2010
6. Lai TL, Lavori PW, Shih MC, et al: Clinical trial designs for testing biomarker-based personalized therapies. Clin Trials 9:141-154, 2012
7. Simon RM, Paik S, Hayes DF: Use of archived specimens in evaluation of prognostic and predictive biomarkers. J Natl Cancer Inst 101:1446-1452, 2009
8. Amado RG, Wolf M, Peeters M, et al: Wildtype KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 26:1626-1634, 2008
9. Barker AD, Sigman CC, Kelloff GJ, et al: I-SPY 2: An adaptive breast cancer trial design in the setting of neoadjuvant chemotherapy. Clin Pharmacol Ther 86:97-100, 2009
10. Esserman LJ, Berry DA, Cheang MC, et al: Chemotherapy response and recurrence-free survival in neoadjuvant breast cancer depends on biomarker profiles: Results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657). Breast Cancer Res Treat 132:1049-1062, 2012
11. Huang X, Ning J, Li Y, et al: Using short-term response information to facilitate adaptive randomization for survival clinical trials. Stat Med 28:1680-1689, 2009
12. Lin C, Buxton MB, Moore D, et al: Locally advanced breast cancers are more likely to present as Interval Cancers: Results from the I-SPY 1 TRIAL (CALGB 150007/150012, ACRIN 6657, InterSPORE Trial). Breast Cancer Res Treat 132:871-879, 2012
13. Zhou X, Liu S, Kim ES, et al: Bayesian adaptive design for targeted therapy development in lung cancer: A step toward personalized medicine. Clin Trials 5:181-193, 2008
14. Ledford H: Clinical drug tests adapted for speed. Nature 464:1258, 2010
15. Freidlin B, Korn EL: Biomarker-adaptive clinical trial designs. Pharmacogenomics 11:1679-1682, 2010
16. Korn EL, Freidlin B: Outcome: Adaptive randomization - Is it useful? J Clin Oncol 29:771- 776, 2011
17. [No authors listed]: Time to adapt. Nature 464:1245-1246, 2010
18. McShane LM, Hunsberger S, Adjei AA: Effective incorporation of biomarkers into phase II trials. Clin Cancer Res 15:1898-1905, 2009
19. Freidlin B, Sun Z, Gray R, et al: Phase III clinical trials that integrate treatment and biomarker evaluation. J Clin Oncol 31:3158-3161, 2013
20. Parmar MK, Barthel FM, Sydes M, et al: Speeding up the evaluation of new agents in cancer. J Natl Cancer Inst 100:1204-1214, 2008
21. Royston P, Barthel FM, Parmar MK, et al: Designs for clinical trials with time-to-event outcomes based on stopping guidelines for lack of benefit. Trials 12:81, 2011
22. Royston P, Parmar MK, Qian W: Novel designs for multi-arm clinical trials with survival outcomes with an application in ovarian cancer. Stat Med 22:2239-2256, 2003 (Pubitemid 36926938)
23. Lièvre A, Bachet JB, Le Corre D, et al: KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res 66: 3992-3995, 2006
24. Kwak EL, Bang YJ, Camidge DR, et al: Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 363:1693-1703, 2010
25. Wu SG, Kuo YW, Chang YL, et al: EML4-ALK translocation predicts better outcome in lung adenocarcinoma patients with wild-type EGFR. J Thorac Oncol 7:98-104, 2012
26. Bayraktar S, Glück S: Molecularly targeted therapies for metastatic triple-negative breast cancer. Breast Cancer Res Treat 138:21-35, 2013
27. Boyle P: Triple-negative breast cancer: Epidemiological considerations and recommendations. Ann Oncol 23:vi7-vi12 (suppl 6) 2012
28. Cortesi L, De Matteis E, Cirilli C, et al: Outcome evaluation in pre-trastuzumab era between different breast cancer phenotypes: A populationbased study on Italian women. Tumori 98:743-750, 2012
29. Dreyer G, Vandorpe T, Smeets A, et al: Triple negative breast cancer: Clinical characteristics in the different histological subtypes. Breast 22:761-766, 2013
30. Brixen LM, Bernstein IT, Bülow S, et al: The survival of patients with stage III colon cancer is improved in HNPCC compared with sporadic cases: A Danish registry based study. Colorectal Dis 15: 816-823, 2013
31. Laghi L, Malesci A: Microsatellite instability and therapeutic consequences in colorectal cancer. Dig Dis 30:304-309, 2012
32. Korn EL, Freidlin B, Abrams JS, et al: Design issues in randomized phase II/III trials. J Clin Oncol 30:667-671, 2012
33. Barthel FM, Royston P, Parmar MK: A menudriven facility for sample size calculation in novel multiarm, multistage randomized controlled trials with a time-to-event outcome. Stata J 9:505-523, 2009
34. Haybittle JL: Repeated assessment of results in clinical trials of cancer treatment. Br J Radiol 44:793-797, 1971
35. Peto R, Pike MC, Armitage P, et al: Design and analysis of randomized clinical trials requiring prolonged observation of each patient: I. Introduction and design. Br J Cancer 34:585-612, 1976 (Pubitemid 8004970)
36. De Roock W, Claes B, Bernasconi D, et al: Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: A retrospective consortium analysis. Lancet Oncol 11:753-762, 2010
37. Khambata-Ford S, Garrett CR, Meropol NJ, et al: Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab. J Clin Oncol 25:3230-3237, 2007 (Pubitemid 47325606)
38. Maughan TS, Adams RA, Smith CG, et al: Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: Results of the randomised phase 3 MRC COIN trial. Lancet 377:2103-2114, 2011
39. Hecht JR, Mitchell E, Chidiac T, et al: A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer. J Clin Oncol 27:672-680, 2009
40. Tol J, Koopman M, Cats A, et al: Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer. N Engl J Med 360:563-572, 2009
41. Adams RA, Meade AM, Madi A, et al: Toxicity associated with combination oxaliplatin plus fluoropyrimidine with or without cetuximab in the MRC COIN trial experience. Br J Cancer 100:251-258, 2009
42. Madi A, Fisher D, Wilson RH, et al: Oxaliplatin/ capecitabine vs oxaliplatin/infusional 5-FU in advanced colorectal cancer: The MRC COIN trial. Br J Cancer 107:1037-1043, 2012
43. Maughan TS, Wilson RH, Williams GT, et al: Developing a biomarker-stratified trial design in advanced colorectal cancer: The MRC FOCUS 3 feasibility study. J Clin Oncol 29, 2011 (suppl; abstr TPS165)